Best of the Week
Most Popular
1. TESLA! Cathy Wood ARK Funds Bubble BURSTS! - 12th May 21
2.Stock Market Entering Early Summer Correction Trend Forecast - 10th May 21
3.GOLD GDX, HUI Stocks - Will Paradise Turn into a Dystopia? - 11th May 21
4.Crypto Bubble Bursts! Nicehash Suspends Coinbase Withdrawals, Bitcoin, Ethereum Bear Market Begins - 16th May 21
5.Crypto Bubble BURSTS! BTC, ETH, XRP CRASH! NiceHash Seizes Funds on Account Halting ALL Withdrawals! - 19th May 21
6.Cathy Wood Ark Invest Funds Bubble BURSTS! ARKK, ARKG, Tesla Entering Severe Bear Market - 13th May 21
7.Stock Market - Should You Be In Cash Right Now? - 17th May 21
8.Gold to Benefit from Mounting US Debt Pile - 14th May 21
9.Coronavius Covid-19 in Italy in August 2019! - 13th May 21
10.How to Invest in HIGH RISK Tech Stocks for 2021 and Beyond - Part 2 of 2 - 18th May 21
Last 7 days
Virgin Media Fibre Broadband Installation - What to Expect, Quality of Wiring, Service etc. - 21st Jun 21
Feel the Inflationary Heartbeat - 21st Jun 21
The Green Superfuel That Could Disrupt Global Energy Markers - 21st Jun 21
How Binance SCAMs Crypto Traders with UP DOWN Coins, Futures, Options and Leverage - Don't Get Bogdanoffed! - 20th Jun 21
Smart Money Accumulating Physical Silver Ahead Of New Basel III Regulations And Price Explosion To $44 - 20th Jun 21
Rambling Fed Triggers Gold/Silver Correction: Are Investors Being Duped? - 20th Jun 21
Gold: The Fed Wreaked Havoc on the Precious Metals - 20th Jun 21
Investing in the Tulip Crypto Mania 2021 - 19th Jun 21
Here’s Why Historic US Housing Market Boom Can Continue - 19th Jun 21
Cryptos: What the "Bizarre" World of Non-Fungible Tokens May Be Signaling - 19th Jun 21
Hyperinflationary Expectations: Reflections on Cryptocurrency and the Markets - 19th Jun 21
Gold Prices Investors beat Central Banks and Jewelry, as having the most Impact - 18th Jun 21
Has the Dust Settled After Fed Day? Not Just Yet - 18th Jun 21
Gold Asks: Will the Economic Boom Continue? - 18th Jun 21
STABLE COINS PONZI Crypto SCAM WARNING! Iron Titan CRASH to ZERO! Exit USDT While You Can! - 18th Jun 21
FOMC Surprise Takeaways - 18th Jun 21
Youtube Upload Stuck at 0% QUICK FIXES Solutions Tutorial - 18th Jun 21
AI Stock Buying Levels, Ratings, Valuations Video - 18th Jun 21
AI Stock Buying Levels, Ratings, Valuations and Trend Analysis into Market Correction - 17th Jun 21
Stocks, Gold, Silver Markets Inflation Tipping Point - 17th Jun 21
Letting Yourself Relax with Activities That You Might Not Have Considered - 17th Jun 21
RAMPANT MONEY PRINTING INFLATION BIG PICTURE! - 16th Jun 21
The Federal Reserve and Inflation - 16th Jun 21
Inflation Soars 5%! Will Gold Skyrocket? - 16th Jun 21
Stock Market Sentiment Speaks: Inflation Is For Fools - 16th Jun 21
Four News Events That Could Drive Gold Bullion Demand - 16th Jun 21
5 ways that crypto is changing the face of online casinos - 16th Jun 21
Transitory Inflation Debate - 15th Jun 21
USDX: The Cleanest Shirt Among the Dirty Laundry - 15th Jun 21
Inflation and Stock Market SPX Record Highs. PPI, FOMC Meeting in Focus - 15th Jun 21
Stock Market SPX 4310 Right Around the Corner! - 15th Jun 21
AI Stocks Strength vs Weakness - Why Selling Google or Facebook is a Big Mistake! - 14th Jun 21
The Bitcoin Crime Wave Hits - 14th Jun 21
Gold Time for Consolidation and Lower Volatility - 14th Jun 21
More Banks & Investors Are NOT Believing Fed Propaganda - 14th Jun 21
Market Inflation Bets – Squaring or Not - 14th Jun 21
Is Gold Really an Inflation Hedge? - 14th Jun 21
The FED Holds the Market. How Long Will It Last? - 14th Jun 21
Coinbase vs Binance for Bitcoin, Ethereum Crypto Trading & Investing During Bear Market 2021 - 11th Jun 21
Gold Price $4000 – Insurance, A Hedge, An Investment - 11th Jun 21
What Drives Gold Prices? (Don't Say "the Fed!") - 11th Jun 21
Why You Need to Buy and Hold Gold Now - 11th Jun 21
Big Pharma Is Back! Biotech Skyrockets On Biogen’s New Alzheimer Drug Approval - 11th Jun 21
Top 5 AI Tech Stocks Trend Analysis, Buying Levels, Ratings and Valuations - 10th Jun 21
Gold’s Inflation Utility - 10th Jun 21
The Fuel Of The Future That’s 9 Times More Efficient Than Lithium - 10th Jun 21
Challenges facing the law industry in 2021 - 10th Jun 21
SELL USDT Tether Before Ponzi Scheme Implodes Triggering 90% Bitcoin CRASH in Cryptos Lehman Bros - 9th Jun 21
Stock Market Sentiment Speaks: Prepare For Volatility - 9th Jun 21
Gold Mining Stocks: Which Door Will Investors Choose? - 9th Jun 21
Fed ‘Taper’ Talk Is Back: Will a Tantrum Follow? - 9th Jun 21
Scientists Discover New Renewable Fuel 3 Times More Powerful Than Gasoline - 9th Jun 21
How do I Choose an Online Trading Broker? - 9th Jun 21
Fed’s Tools are Broken - 8th Jun 21
Stock Market Approaching an Intermediate peak! - 8th Jun 21
Could This Household Chemical Become The Superfuel Of The Future? - 8th Jun 21
The Return of Inflation. Can Gold Withstand the Dark Side? - 7th Jun 21
Why "Trouble is Brewing" for the U.S. Housing Market - 7th Jun 21
Stock Market Volatility Crash Course (VIX vs VVIX) – Learn How to Profit From Volatility - 7th Jun 21
Computer Vision Is Like Investing in the Internet in the ‘90s - 7th Jun 21
MAPLINS - Sheffield Down Memory Lane, Before the Shop Closed its Doors for the Last Time - 7th Jun 21
Wire Brush vs Block Paving Driveway Weeds - How Much Work, Nest Way to Kill Weeds? - 7th Jun 21
When Markets Get Scared and Reverse - 7th Jun 21
Is A New Superfuel About To Take Over Energy Markets? - 7th Jun 21

Market Oracle FREE Newsletter

How to Protect your Wealth by Investing in AI Tech Stocks

SILO Stock The Most Undervalued Play In Psychedelic

Companies / BioTech Dec 16, 2020 - 03:08 PM GMT

By: Joshua_Rodriguez

Companies

Psychedelics has become a hot topic among the investing community. They’ve been around for some time, and for the most part, these party favors found in dorm rooms are looked at in a negative connotation.

But what if I told you that psychedelics could be the answer to some of the most difficult-to-treat medical conditions.

I know it sounds strange, but oftentimes, there’s therapeutic benefit found in the strangest things, and believe it or not, psychedelics have been used as a medicine for hundreds of years.

No, you’re not going to go to the doctor with a flu and be prescribed psilocybin or LSD, but medicine men among various cultures, including Native Americans, have used these mind-altering compounds as an option for the treatment of various ailments. So, psychedelics as a medicine aren’t anything new.

Today, there are a handful of biotech companies looking to take our understanding of how psychedelics can improve things like cognition in Alzheimer’s and Parkinson’s disease patients, frame of thought in depression patients, and ability to live a relatively normal life in PTSD patients.


Ultimately, there are several ailments that compounds like psilocybin, LSD, and MDMA may provide the answer for.

Of course, medicine is big business. So, should these psychedelic therapies prove effective, they’ll come with the potential to produce tremendous profitability for the companies that develop them. As such, investor interest surrounding this concept has been ramping up in recent years.

With only a handful of biotechs studying psychedelics as a therapeutic option, and investor demand running high in the space, it’s not surprising that the vast majority of companies focused on this compelling science are overvalued on Wall Street.

Nonetheless, there’s one company in the space that has a clear and overwhelming undervaluation that I believe represents a tremendous opportunity for investors.

That company is Silo Pharma (OTCQB: SILO).

Skip to What You Want to Read

(Links below will jump to headings in the article. This section is required for formatting on the publication the article was written for.)

What Is Silo Pharma?

What Is Psilocybin?

SILO Is Tapping Into Massive Markets

Silo Pharma’s Closest Comp Climbed Over 700% This Year

What’s Next for SILO?

Final Thoughts

What Is Silo Pharma?

Silo Pharma is a clinical-stage biotechnology company that’s focused on the use of psychedelics as a treatment option for some of the world’s most debilitating psychological conditions.

The company is working on putting together a Scientific Advisory Board like nothing else seen in a publicly traded company. However, a Scientific Advisory Board means nothing if you’re not in the process of developing something meaningful.

Recently Silo Pharma announced that it would be hitting the clinic for a Phase 2B clinical study. In particular, the study is designed to examine the effects of repeated low doses of psilocybin and LSD on cognitive and emotional dysfunction in Parkinson’s disease.

Importantly, SILO won’t have to foot the bill on this one by themselves. In fact, this is an investigator-sponsored study, with Dr. Kim Kuypers, Associate Professor of the Department of Neurology and Psychopharmacology at Maastricht University, will act as the Investigator Sponsor of the Phase 2B clinical study.

The company is also researching ways to treat conditions like fibromyalgia and general anxiety disorder (GAD) using psychedelic therapies. For more information on Silo Pharma, click here.

What Is Psilocybin?

Psilocybin is the active ingredient found in magic mushrooms and one of the most important compounds being addressed by Silo Pharma. Used by medicine men for hundreds of years, there is plenty of literature that backs psilocybin up as a potential treatment for psychiatric disorders, personal and spiritual development, and creative enhancement.

More recently, the compound has been the subject of several clinical studies, which have only served to prove that old-school medicine men from lesser-developed cultures are onto something here.

SILO Is Tapping Into Massive Markets

Should Silo Pharma be successful in proving that psychedelic compounds are an effective treatment for the ailments it’s targeting, it will tap into massive markets. Just take a look below:

  1. Parkinson’s Disease. By 2025, it is expected that the Parkinson’s disease treatment market will grow to be worth about $6 billion annually.
  2. Fibromyalgia. Fibromyalgia treatments are expected to drive more than $3.6 billion in revenue for the companies that provide them by the year 2026.
  3. GAD. Finally, the GAD market is expected to grow to be worth $7.5 billion by 2023.

Keep in mind, when we talk about SILO, we’re talking about a stock with a market cap of just $35 million! Should the company tap into any of these markets, even in a very small way, it would be enough to generate significant revenue.

Silo Pharma’s Closest Comp Climbed Over 700% This Year

With a title like, “SILO Stock: The Most Undervalued Play In Psychedelics,” it’s only fitting that I point to the extreme undervaluation of the stock out here.

To get a feel for just how undervalued the stock is, all you need to do is look at its closest comparable stock, Mind Medicine (OTC: MMEDF). Like Silo Pharma, Mind Medicine is currently in Phase 2 development of psychedelics as a therapeutic option.

In particular, the company is assessing small doses of LSD as a potential option for patients with anxiety, and producing promising results in the process. However, the stock has already caught the attention of investors, and the potential for a dramatic run in any near-term has largely come and gone.

In fact, this year alone, MMEDF has climbed by more than 700%. Today, the company is worth more than $900 million. That’s right, this Phase 2 clinical-stage biotech is closing in on a billion dollar valuation.

At the same time, Silo Pharma is sitting on the same stage, but due to the fact that it’s not in the spotlight, remains overwhelmingly undervalued. While MMEDF trades with a market cap over $900 million, SILO stock trades with a market cap of just $35 million.

What’s Next for SILO?

Moving forward, Silo Pharma is one to watch closely. First and foremost, the Phase 2B clinical study that’s just around the corner will likely act as a major catalyst. With plenty of literature suggesting strong potential efficacy of psychedelics among the Parkinson’s disease patient population, there’s a high probability of success.

Should the study be successful, it will set the stage for tremendous growth ahead. After all, should the study go well, the company will likely move into late-stage development, garnering the attention of investors and leading to a potential run the likes of what we saw from MMEDF so far this year.

Final Thoughts

The bottom line here is simple. Psychedelics are far more than recreational drugs. Throughout history, they have been used to address some of the most debilitating conditions by medicine men around the world. Today, the scientific community is catching onto the potential power of these compounds.

At the moment, there are only a few companies assessing these compounds, with the vast majority of them being heavily overvalued. However, SILO seems to be the one play in the space that’s heavily undervalued, creating the potential for dramatic gains ahead.

This is a paid advertisement. The views expressed above are those of the author. Silo Pharma played no role in the development or editing of this article.

By Joshua Rodriguez

© 2020 Copyright Joshua Rodriguez - All Rights Reserved

Disclaimer: The above is a matter of opinion provided for general information purposes only and is not intended as investment advice. Information and analysis above are derived from sources and utilising methods believed to be reliable, but we cannot accept responsibility for any losses you may incur as a result of this analysis. Individuals should consult with their personal financial advisors.


© 2005-2019 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in